🚨 Big News for Alzheimer’s Patients in Europe The CHMP has officially recommended Leqembi (lecanemab) for treating early Alzheimer’s disease. And this matters, because it’s the first treatment in Europe that may slow disease progression. But here’s the reality: The waiting isn’t over. 🔗 What happens next: - The European Commission must make Leqembi’s approval official—this takes over two months. - After that, each EU country begins its own process for pricing, reimbursement, and local launch. On average, this can take as little as 133 days in Germany or as long as 899 days in Romania, highlighting the stark inequalities still present across Europe. ⏳ Why waiting is an issue: Leqembi is only effective in the early stages of Alzheimer’s, a window that typically lasts 2–4 years. It’s already been nearly two years since Leqembi’s first FDA approval, and many patients who could have benefited have progressed beyond this critical stage. For those still eligible, every single day counts. ✨At Everyone.org, we believe waiting shouldn’t be part of the treatment plan. Patients can access Leqembi now, regardless of where they live. Health equity stats here: https://everyone.org/ #Alzheimers #Leqembi #AccessToMedicine #HealthcareEquity #EveryoneOrg #CHMP #Alzheimernederland #dementie #teameveryone
Everyone.org’s Post
More Relevant Posts
-
GENERAL MANAGEMENT I CHANGE MANAGEMENT I P&L MANAGEMENT I COMMERCIAL LEADERSHIP I PATIENT CENTRICITY I NEW LAUNCHES I ARTIFICIAL INTELLIGENCE I
Glad to see this piece from Rippon in the New Statesman, urging the new Government to take action to ensure patients in the UK are front of the queue for new medicines. A really interesting read on the implications of the current situation, and opportunities for change. In particular, there is a clear need for the new Labour Government to champion reform that ensures access to multi-indication medicines. By addressing this and other challenges, the system will be set up to receive future innovations and get them to patients faster. #HealthcareInnovation #PatientAccess #LifeSciences #SanofiUK #NHS #IndicationBasedPricing
I was very pleased to share my thoughts in a New Statesman article on how the new Government can address the barriers preventing innovative medicines reaching patients in the UK. One much-needed solution is for access to treatments that address different conditions, known as ‘multi-indication’ medicines. The Government must champion reform that evolves the outdated policy that is causing UK patients to miss out on important treatment options. We can’t afford to miss this crucial opportunity to ensure the system is fit for the future and that patients can benefit from exciting developments in science. I’d be delighted to hear your thoughts after reading my piece here: 👇 https://lnkd.in/eChM3jx6 #accesstoinnovation #healthcare #sanofiUK #NewStatesman
A prescription for success: improving the UK's access to new medicines
newstatesman.com
-
Yesterday, Sen. Bernie Sanders (I-Vt.), announced he is launching an investigation into the pricing of Novo Nordisk's GLP-1 based medicines. Sen. Sander's letter stands on a shaky foundation, built on cherry-picked data and ignores evidence that the medicines are priced in a cost-effective manner. Efforts to address affordability should be based on validated evidence that takes the entire innovation ecosystem into account. Congress should also prioritize passage of The Treat and Reduce Obesity Act (TROA), bipartisan, bicameral legislation that would expand coverage of health care specialists and weight management treatments for Medicare patients. https://lnkd.in/eUfZeVt7
Sanders launches politically motivated investigation into revolutionary, cost-effective diabetes and obesity medicines
https://bio.news
-
Trilingual advocate succeeding in hi-profile/complex Public Policy files | #AIinHealthcare 🏥 | Life Sciences 💊 | Government Affairs 🏛️ | Patients-Seniors Advocacy 😷 | Writing ✍️ | Spokesperson 🗣️ | Moderator-MC 🎤 |
As I've been arguing here on LinkedIn, in public fora, advocacy with elected officials, and in countless conversations for two-decades, national #pharmacare -- as envisaged by its proponents -- is not a policy for the future of #cdnhealth, especially in this era of accelerating #healthcareinnovation, adoption of #precisionmedicine across the spectrum of diseases, and movement to solving/preventing disease as the future. Of course and absoulutey, let's fill the gaps for our fellow citizens and residents who are un-insured and under-insured ASAP, like yesterday for better #healthequity. This requires public- and private-sector inspired and intelligent #leadership as opposed to ideological and ill-advised #legislation. And let’s get on with solutions that transform #healthcare for all Canadians like real #primarycare reform, doubling down on evidence-based investing or in new meds and med tech, incorporation of #aiinhealthcare to address some labour gaps, addressing the four horseman of the #chronicdiseases apocalypse — heart disease, cancer, diabetes, demnentia — and a real and sustained #rarediseases effort. Canadian Chamber of Commerce https://lnkd.in/euQV7hDb
The New Pharmacare Plan Is Expensive and Restrictive - Canadian Chamber of Commerce
https://chamber.ca
-
Today, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new dementia drug, lecanemab, for use in the UK. However, it is unlikely that the drug will be available for use on the NHS in England and Wales after a decision from NICE that it is not cost effective. Unless this position changes, only those who can afford to pay the estimated annual cost of £20,000 to buy lecanemab privately will benefit from this potentially life-changing treatment. Yet again it seems like people with dementia are being pushed to the back of the queue when it comes to NHS spending. We understand that this drug is not a ‘silver bullet’ but it’s probably the most important first step we can take on a journey towards an effective disease modifying treatment. As far as we’re concerned this is fundamentally about the human rights of people with dementia to receive treatment. We will be doing all we can to influence and respond to NICE’s consultation on lecanemab, and we hope that the independent Scottish Medicines Consortium will reach a positive decision. Read more here – https://lnkd.in/e58Teacr If you have been affected by today’s decision and require information or emotional support, please contact our 24-hour Freephone Dementia Helpline at 0808 808 300, or email helpline@alzscot.org.
-
-
This is great news for Medicare covered patients needing Alzheimer's progression reducing drugs. However, the use of registries piques my interest. Do you think its important to go through registration of specific conditions to avail Medicare benefits, and not for others? Learn more from article below. #alzheimerscare #Medicare
Medicare plans to cover approved Alzheimer’s drugs, Brooks-LaSure says
https://www.mcknightshomecare.com
-
🏴 𝐒𝐜𝐨𝐭𝐥𝐚𝐧𝐝 𝐡𝐚𝐬 𝐛𝐞𝐜𝐨𝐦𝐞 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐔𝐊 𝐧𝐚𝐭𝐢𝐨𝐧 to approve Eli Lilly's Mounjaro (tirzepatide) for obesity treatment under the NHS. This landmark decision by the Scottish Medicines Consortium (SMC) allows adults with a BMI of 30 kg/m² or more, and at least one weight-related condition, to access this innovative therapy. Mounjaro, 𝐨𝐫𝐢𝐠𝐢𝐧𝐚𝐥𝐥𝐲 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐞𝐝 𝐟𝐨𝐫 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭, has shown substantial efficacy in weight reduction, marking a crucial step in addressing obesity—a major public health challenge. This proactive move sets Scotland apart, as the NICE - National Institute for Health and Care Excellence in England proposes a higher BMI threshold of 35 kg/m². The final guidance from NICE is expected in October 2024. Find out more here ➡ 🔗 https://lnkd.in/eXsBHi5j #Healthcare #Pharmaceuticals #ObesityTreatment #MarketAccess #NHS #NICE #PharmaUpdates #PatientAccess
-
Nice piece about significant adverse consequences of IRA on drug development!
What an amazing way to close out #rarediseaseday2024! The first line of the Executive Office of the President's read-out from last night's White House Rare Disease Forum says it all: "President Biden has made it clear: we must accelerate the development of treatments and cures for rare diseases and boost support for families facing health challenges." It is so exciting to hear the administration commit $48 million through the Advanced Research Projects Agency for Health (ARPA-H) for a project that leverages #artificialintelligence #ai to find new uses for already FDA-approved drugs to address the 95% of #rarediseases that currently lack safe and effective treatment options. At the same time, paradoxically, the #inflationreductionact #IRA penalizes the rare disease community for doing exactly this drug repurposing! Under current law, as soon as an #orphandrug receives a designation for a second rare disease to unlock the research incentives that allow the drug to be developed for the second rare disease it looses exclusion from the Centers for Medicare & Medicaid Services Drug Price Negotiation Program. None-withstanding that the drug cannot be market for the second disease at that time (it on average takes 4.5 years for a rare disease drug to move from designation to approval) or that the drug may never actually be approved for the second disease - many orphan drugs never make it to approval with designations outnumbering approvals 7:1! During today's House Energy and Commerce Health Subcomittee hearing we heard a LOT about the #IRA and what changes may or may not be needed. Unfortunately, what we did NOT hear was a discussion about these common-sense fixes we at the National Organization for Rare Disorders as part of a coalition of 170 patient advocacy groups have been advocating for since the drug price negotiation program took shape - small technical corrections that would protect vital research incentives and without whom the new ARPA-H drug repurposing program may face unsurmountable headwinds!
-
Global Communications leader with 20+ years experience in Pharma FMCG, Forbes 2024 Top Comms Director (Spain), Scientific Comms expert - views are my own, and do not necessarily reflect those of my employer
The difference in the time patients can access new medicines in countries across Europe is staggering! The 2024 WAIT report has just been published highlighting that the average time for patients to access new medicines across Europe is 531 days. Importantly, it ranges from as little as 126 days in Germany to a staggering 804 days in Poland (that is well over two years!). It is essential for people who suffer from diseases to get access to the innovation in treatment solutions as quickly as possible. For patients, every day counts, so I hope this report is going to help address this inequality across Europe as soon as possible. #EFPIA, #accesstomedicines, #innovation, #healthcare https://lnkd.in/efCDdcQW
New data from EFPIA reveals multiple factors leading to unequal access to medicines for patients across Europe
efpia.eu
-
Dedicated Trainee Clinical Research Coordinator | Committed to Supporting Clinical Trials and Advancing Healthcare Innovation
🎉 Exciting News in Healthcare! 🎉 I'm thrilled to share that the U.S. Food and Drug Administration has just approved Rezdiffra (resmetirom), the first-ever treatment for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver scarring (fibrosis). This groundbreaking approval represents a significant advancement in combating liver disease, offering hope and improved outcomes for patients. NASH, a severe form of fatty liver disease, has been a challenging condition to treat effectively. However, with the approval of Rezdiffra, patients now have a new option to manage this condition alongside diet and exercise. As we continue to push the boundaries of medical innovation, let's celebrate this milestone and look forward to the positive impact it will have on individuals affected by NASH. Together, we're making strides towards a healthier future. #HealthcareInnovation #NASHTreatment #LiverDiseaseAwareness Madrigal Pharmaceuticals 🌟🩺
-
-
Spotlight on selected 2024 FDA Approvals: Advancing Healthcare 🌟 This year, groundbreaking FDA drug approvals are paving the way for a healthier, brighter future. Here's a focused look at key areas where they are making a meaningful impact on patient care and treatment outcomes: 💓 Heart Hypertension is a condition marked by persistently high blood pressure, increasing the risk of heart attacks and strokes. 💊Tryvio: A game-changer that helps lower blood pressure and reduce cardiovascular events. 🩸 Kidney Anemia due to chronic kidney disease (CKD) is a common complication that affects many CKD patients. 💊Vafseo: A treatment designed to manage anemia and improve outcomes for CKD patients. ⚕️ Liver Primary biliary cholangitis (PBC), a chronic liver disease that can lead to severe liver damage if untreated. 💊Iqirvo & Livdelzi: These drugs, in combination with ursodeoxycholic acid (UDCA), provide an effective treatment option for PBC. 🌬️ Lung Pulmonary arterial hypertension (PAH): a rare, progressive disease that affects blood vessels in the lungs. 💊Winrevair: Offers improved quality of life for patients with PAH. Chronic obstructive pulmonary disease (COPD): a progressive condition that makes breathing difficult. 💊Ohtuvayre: Provides relief and better management of COPD symptoms. Each approval is a significant step toward improving patient outcomes and tackling serious health challenges. 💙 #FDAApprovals2024 #InnovationInHealthcare #Delta4 #newtreatments #PBC #CKD #COPD
-
Socials + Outreach @everyone.org | Marketing and Outreach Specialist | Content Creation
1mo🎉